Clinical Trial

Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated January 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to evaluate the immunogenicity and safety of a single injection of two dose levels of ABO1105 in adults aged 50 years or above.
Trial Details
NCT Number NCT07289542
Lead Sponsor Suzhou Abogen Biosciences Co., Ltd.
Collaborators: Abogen Biosciences (Shanghai) Co., Ltd
Conditions Respiratory Syncytial Virus
Enrollment 420 participants
Start Date 2025-09-15
Primary Completion 2026-01-07 (estimated)
Study Completion 2027-10-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-17